{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"12.8","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"11.2","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"description":"The percentage of participants with bone marrow abnormalities (eg, myelodysplastic syndrome, monosomy 7) based on analysis of bone marrow biopsy and aspirate samples using cytogenetics and fluorescence in situ hybridization.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants enrolled under the protocol supplement in the EU, Switzerland, or Turkey received weekly romiplostim for 3 years and had a bone marrow biopsy at baseline and year 1.","id":"OG000","title":"Cohort 1"},{"description":"Participants enrolled under the protocol supplement in the EU, Switzerland, or Turkey received weekly romiplostim for 3 years and had a bone marrow biopsy at baseline and year 2.","id":"OG001","title":"Cohort 2"}],"paramType":"NUMBER","populationDescription":"Bone marrow analysis set participants with an on-study bone marrow abnormality assessment","reportingStatus":"POSTED","timeFrame":"Year 1 (Cohort 1) and year 2 (Cohort 2)","title":"Percentage of Participants Who Developed Bone Marrow Abnormalities","type":"PRIMARY","unitOfMeasure":"percentage of participants"}